EIKN · Eikon Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Josh Wolfe | ▼ Sell | Other | 2,294,653 Shares held | 2/6/2026 | View profile |
| Lux Venture Partners V, LLC | ▼ Sell | Other | 2,294,653 Shares held | 2/6/2026 | View profile |
| Foresite Capital Management IV, LLC 10% Owner | ▲ Buy | Open Market | 1,318,983 Shares held | 2/4/2026 | View profile |
| Roger M. Perlmutter See remarks | ▼ Sell | Other | 284,857 Shares held | 2/6/2026 | View profile |
| Kenneth C. Frazier Executive Chair | ▲ Buy | Open Market | 111,111 Shares held | 2/4/2026 | View profile |
| Column Group IV GP, LP | ▲ Buy | Open Market | 89,200 Shares held | 9/3/2026 | View profile |
Transaction History
| Column Group IV GP, LP | ▲ Buy | Open Market | 89,200 | $1.0M | 9/3/2026 |
| Josh Wolfe | ▼ Sell | Other | 2,155,765 | — | 2/6/2026 |
| Lux Venture Partners V, LLC | ▼ Sell | Other | 2,387,705 | — | 2/6/2026 |
| Lux Venture Partners V, LLC | ▼ Sell | Other | 1,151,540 | — | 2/6/2026 |
| Lux Venture Partners V, LLC | ▼ Sell | Other | 2,155,765 | — | 2/6/2026 |
| Roger M. Perlmutter | ▼ Sell | Other | 284,857 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 1,296,629 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 1,403,568 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 110,928 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 44,249 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 47,898 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 3,785 | — | 2/6/2026 |
| Column Group IV GP, LP | ▼ Sell | Other | 688,283 | — | 2/6/2026 |
| Josh Wolfe | ▼ Sell | Other | 2,387,705 | — | 2/6/2026 |
| Josh Wolfe | ▼ Sell | Other | 1,151,540 | — | 2/6/2026 |
| Column Group IV GP, LP | ▲ Buy | Open Market | 1,437,323 | $25.9M | 2/6/2026 |
| Column Group IV GP, LP | ▲ Buy | Open Market | 49,556 | $892K | 2/6/2026 |
| Column Group IV GP, LP | ▲ Buy | Open Market | 630,881 | $11.4M | 2/6/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 38,133 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 408,725 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▲ Buy | Open Market | 55,555 | $1000K | 2/4/2026 |
| Lux Venture Partners V, LLC | ▲ Buy | Open Market | 138,888 | $2.5M | 2/4/2026 |
| Lux Venture Partners V, LLC | ▲ Buy | Open Market | 138,888 | $2.5M | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 1,340,878 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 335,521 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 37,855 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 229,428 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 697,885 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 37,855 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 1,626 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 67,207 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 458,855 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 348,942 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 37,855 | $0 | 2/4/2026 |
| Foresite Capital Management IV, LLC | ▼ Sell | Other | 922 | $0 | 2/4/2026 |
| Kenneth C. Frazier | ▲ Buy | Open Market | 111,111 | $2.0M | 2/4/2026 |
| Josh Wolfe | ▲ Buy | Open Market | 138,888 | $2.5M | 2/4/2026 |
| Josh Wolfe | ▲ Buy | Open Market | 138,888 | $2.5M | 2/4/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
EIKN sees institutional buying following NVIDIA and Merck moves
Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.
EIKN sees institutional buying following NVIDIA and Merck moves. Institutional investors have increased their purchases of Eikon Therapeutics shares, a trend highlighted in a Benzinga article that points to similar buying activity in NVIDIA and Merck. The move suggests growing confidence in EIKN’s prospects. With the stock trading near its 52‑week low and an RSI of 36.6, the new buying activity could be a sign of potential support at the $9.84 level.